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This study focuses on the eﬀects of long-term renin-angiotensin system suppression and/or incretin mimetic therapies on the
regulation and binding aﬃnity of GLP-1 to its receptor in the coronary endothelium (CE) and cardiomyocytes (CMs) of type
1 diabetic male Sprague-Dawley rats. The groups assessed are normal (N), streptozotocin-induced diabetic (D), Insulin treated
(DI), Exendin-4 treated (DE), Aliskiren treated (DA), cotreated with Insulinand Aliskiren(DIA) andcotreated with exendin-4 and
Aliskiren (DEA). Heart perfusion with 125I-GLP-1 was performed to estimate GLP-1 binding aﬃnity (τ = 1/k − n)t oi t sr e c e p t o r
in the heart. Western Blotting was assessed to determine the expression variation of GLP-1 receptor in the heart. Plasma GLP-1
levels were measured using Enzyme-Linked Immunosorbent Assay (ELISA). Diabetes decreased the τ value on CE and increased
it on CMs compared to normal.The combinationof Exendin-4 with Aliskiren showed a normalizingeﬀect on the binding aﬃnity
of GLP-1 at the coronary endothelium, while at the cardiomyocyte level Exendin-4 treatment alone was the most eﬀective.
1.Introduction
Diabetes mellitus currently aﬀects more than 170 million
individuals worldwide [1]. Other than hyperglycemia, dia-
b e t e sm e l l i t u sc a nc a u s ea2 - 3 - f old increase in the occurrence
of cardiovascular disease (CVD) [2]. Both manifestations
are easily triggered by oxidative stress, glucose intolerance,
and inﬂammation; hence, they probably exhibit similar un-
derlying processes that lead to their pathogenesis [1]. The
incretin hormone, glucagon-likepeptide-1(GLP-1), playsan
importantroleinmaintaining glucosehomeostasis. Receptor
signaling on the pancreas leads to enhanced insulin biosyn-
thesis, secretion, and β-cell proliferation [3, 4]. GLP-1 has
also been suggested to ameliorate left ventricular function,
because of its antiapoptotic and insulin-like properties [5].
The incretin eﬀect, described as the enhanced response of
insulin release after an oral glucose load, has been shown
to be reduced in diabetes mellitus [6]. This defect in GLP-
1 secretion has been reported in both Type 1 and Type 2
diabetes mellitus [7]. On the other hand, a recent study
reported that GLP-1 levels are not decreased in type 2
diabetic patients [8]. Therefore, the eﬀect of diabetes mel-
litus on the secretion of GLP-1 is a controversial issue. The
renin angiotensin system (RAS) controls and regulates the
electrolyte-ﬂuid homeostasis and blood pressure by acting
on organs in the cardiovascular, renal, and adrenal systems
[9]. Clinically, RAS blockage has been proposed to alleviate
diabetic complications. In 2007, Aliskiren, a potent renin
inhibitor, was approved for clinical use. It is unique due to
its low molecular weight, its orally active property, and its
nonpeptide nature that makes it resistant to enzymatic deg-
radation [10, 11]. Aliskiren binds to renin, hence blocking
the attachment of angiotensinogen to it and its consequent
conversion to angiotensin I [12]. It was also shown to reduce2 Experimental Diabetes Research
left ventricular hypertrophy as eﬃciently as angiotensin re-
ceptor blockers (ARBs) [13]. This study aims to assess the
eﬀect of the GLP-1 analogue, Exendin-4, and the renin in-
hibitor, Aliskiren, and their cotreatment on the binding ki-
netics of GLP-1 to its receptor at both the coronary endothe-
lial and cardiomyocyte levels in type 1 diabetic rats.
2.Materialsand Methods
The experiments were conducted with prior approval of
the Institutional Review Board and Animal Care Committee
of the American University of Beirut (AUB). All animals
were handled, treated, and sacriﬁced in accordance with the
guidelines of the American Association for Laboratory
Animal Sciences (AALAS) on Humane Care and Use of
Laboratory Animals. For all the parameters, per animal per
group,mentionedbelow,theexperimentaldataarepresented
as mean value ± standard error of mean (SEM). Student’s
t-test was employed to estimate the signiﬁcance among the
diﬀerent experimental groups. P values of less than .05 were
considered signiﬁcant.
2.1. Animals. Male Sprague-Dawley rats (6 weeks old,
175–250gbodyweight) were purchased from Harland, The
Netherlands, and bred at the Animal House Unit, American
University of Beirut. They were housed at four rats per cage
(24 animals per group), fed Purina pellets and tap water ad
libitum, and kept for a period of one month at a constant
temperature with a daily 12h light:12h dark cycle.
2.2. Treatment and Monitor Plan. Rats were divided into
seven groups as follows: Group N (n = 24): normal
control, received a placebo by oral gavage (tap water,
4mL/kgbodyweight), once daily (qd); Group D (n = 24):
rats with diabetes type 1 were injected intraperitoneally
(ip) with 3cc/kgbodyweight normal saline solution (NSS),
twice daily (bid), and were given placebo (water) by oral
gavage (4cc/kgbodyweight, qd); Group DI (n = 24):
rats with diabetes type 1 were injected ip with bovine
insulin (Sigma Chemical Company, St. Louis, MI, USA),
0.28unit/cc, 1unit/kgbodyweight, once in the morning
(qAM), and subcutaneous insulin glargine (Lantus) injec-
tions (1.25unit/cc, 1unit/kgbodyweight) (Sanoﬁ-Aventis,
USA), once in the afternoon (qPM); Group DE (n = 24):
rats with diabetes type 1 were injected intraperitoneally (ip)
with Exendin-4 (0.03μg/kgbodyweight, bid) (Sigma Chem-
ical Company, St. Louis, Mich, USA); Group DA (n =
24): rats with diabetes type 1 were administered Aliskiren
(50mg/kgbodyweight, qd) (Novartis Pharma Stein AG,
Switzerland) by oral gavage. Group DIA (n = 24): rats
with diabetes type 1 were injected ip with bovine insulin
qAM, injected subcutaneously insulin glargine qPM, and
were administered Aliskiren (50mg/kgbodyweight, qd) by
oral gavage. Group DEA (n = 24): rats with diabetes type 1
were injected intraperitoneally (ip) with Exendin-4 and were
administered Aliskiren (50mg/kgbodyweight, qd) by oral
gavage.
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Figure 1: Standard curve for GLP-1.
2.3. Induction of Diabetes. Groups D, DI, DE, DA, DIA and
DEA were induced to type 1 diabetes mellitus by a single
intravenous injection of streptozotocin (STZ; 85mg/kgbw)
(Sigma Chemical Co., Saint Louis, Mo, USA) in saline acidi-
ﬁed to pH 4.5 with 0.1M citrate buﬀer[14]. Three dayslater,
nonfasting blood glucose level was measured using Accu-
Chek (Accu-Chek Instant Test; Roche Diagnostics GmbH,
Mannheim, Germany); a level of ≥250mg/dL conﬁrmed
type 1 diabetes mellitus.
2.4. Body Weight and Blood Glucose. All the animals were
weighed weekly, and blood glucose levels were determined
[15] using Accu-Chek (Accu-Chek instant test, Roche Diag-
nostics GmbH, Mannheim, Germany) weekly during one
month of treatment.
2.5. Cardiac Hypertrophy Was Assessed Macroscopically. After
one month of treatment, wet heart weight was recorded
(N = 16). Heart weight (H.W.) to body weight (B.W.) ratio
(H.W./B.W.) was determined and averaged that served as an
index for comparison among diﬀerent groups.
2.6. Enzyme-Linked Immunosorbent Assay of GLP-1. Rats
were anesthetized, and blood was collected from the sub-
lingual vein on days 1, 7, 14, 21, and 28 of the treatment
period, at a constant time range of 9 to 10 AM. For each
1mL blood, 10μL of DPP-IV enzyme inhibitor was added
within 30 seconds of the collection of blood to prevent
GLP-1 degradation. Enzyme-Linked Immunosorbent Assay
(ELISA) was performed to detect the levels of active GLP-
1 (7–36 and 7–37) in the plasma of the rats using the
Glucagon-Like Peptide-1 (Active) ELISA kit (ELISA KIT
LINCO Research, Mish, USA). Standards of known concen-
trations of active GLP-1 and the samples were added to the
96-well plate. GLP-1 detection conjugate and substrate were
added according to the kit manual to generate a reaction,
and the plate was read on the Fluorescent Plate reader at
wavelengthsof355/460nm.Arelativeﬂuorescentunit(RFU)
curve was plotted using these standards (Figure 1). Since the
amount of ﬂuorescence generated is directly proportional to
the concentration of GLP-1, the concentration of GLP-1 in
the plasma samples can be derived.Experimental Diabetes Research 3
25 20 15 10 5 0
(minutes)
0
200
400
600
800
1
0
−
1
8
m
o
l
e
s
p
e
r
0
.
5
m
L
p
e
r
f
u
s
a
t
e
a(1) = 0.876+/ −0.05
a(2) = 1.756+/ −0.05
a(3) = 91.73+/ −1
Chi square = 1.25
Figure 2: A representative time dependent [125I]-GLP-1 concen-
tration curve in the eﬄuent collected during heart perfusion in
Normal group (N) at the level of endothelium. Data points were
curve ﬁtted using equation 2 as described by Haddad et al. [17].
The values a(1), a(2), and a(3) were employed to calculate kn and
k−n.
2.7. Surgical Procedures. After one month of treatment,
the rats were weighed and anesthetized by intramuscular
injection of Ketamine (100mg/kgbodyweight) (AUB-MC,
Lebanon) and Xylazine (10mg/kgbodyweight) (Interchem-
ie, Casternary, Holland) and then ﬁxed to a heating pad to
prevent rapid cooling. The anterior chest wall was excised
longitudinally up to the xyphoid, thus exposing the entire
thoracic cavity and the heart for perfusion [16].
2.8. Perfusion of Rat Heart with 125I-GLP-1. The major
veins and arteries including the inferior, superior vena cava,
pulmonary artery, and pulmonary vein were ligated. In
addition, the left and right lungs were tied in order to block
the blood ﬂow to them and to other organs. The aorta
was slightly cut, and a polyethylene catheter was inserted
(from cephalad to caudad) into its lumen to reach the aortic
valve. The right atrium was punctured, and another catheter
was inserted to carry out the perfusate. Both catheters were
secured with a suture [17]. A 50mL syringe ﬁlled with
heparinized Ringer-Lock buﬀer containing 20meq/L K+,
oxygenated with 95%O2,5 %C O 2 at 37◦Cl i n k e dt oa ni n f u -
sion pump was attached to the inlet. This solution cleared
the heart from blood and clots for 15 minutes; infusion
of a Ringer-Lock buﬀer solution for another 15 minutes
cleared the heart from heparin. These steps were followed
by the perfusion of a buﬀer containing 8.25 × 10−4 nM/L
[125I] GLP-1 (speciﬁc activity, 2200Ci/mmol; Santa Cruz
Biotech., Calif, USA) at a rate of 1mL/min. Heart perfusion
was performed in 16 rats from each set divided into one
subgroup (n = 8) perfused with buﬀer alone; and the other
(n = 8) perfused with 20mmol/L 3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate (CHAPS; Sigma),
which has a mild detergent action, to slough oﬀ the capillary
endotheliallining.Theperfusatewascollectedfor20minutes
at speciﬁc time intervals (between 0-1, 1-2, 2-3, 3-4, 4-5, 5-
6, 6-7, 7-8, 8-9, 9-10, 10–12, 12–15, 15–20 minutes); after
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Figure 3 :B o d yw e i g h t so fr a t si nt h es e v e ne x p e r i m e n t a lg r o u p s
after 1 month of treatment (N = 24).
each collection, 500μL of the sample was put in a liquid
scintillation vial containing 4mL of Ecolume scintillation
cocktail, which was later assayed for radioactivity by a liquid
scintillation analyzer. The surgical procedure and perfusion
model as described by Bikhazi et al. [16] and Haddad et al.
[17] were followed to determine the binding kinetics of 125I-
GLP-1 (speciﬁc activity, 2200Ci/mmol; Santa Cruz Biotech.,
Calif, USA) to its receptor at the level of endothelial cells and
cardiac myocytes (Figure 2).
2.9. Western Blot. After the thoracic cage was excised and the
inferior vena cava was cut, a ﬁne needle was inserted in the
beating heart washing it several times with saline water. The
heart was then removed and immediately put in a beaker
containing isopentane and dry ice. When the heart was snap
frozen, it was cut transversely into 4 sections: apex, S1, S2,
and base. The S1 heart sections were later homogenized,
and proteins were extracted using Sucrose Hepes Tris-Buﬀer
and a serine protease inhibitor, PMSF. 150μgo ft h es a m p l e
protein was loaded and separated by 10% polyacrylamide
gel electrophoresis for 1 hour and 30 minutes. The bands
were then transferred on a nitrocellulose membrane via
the Transblot unit, PowerPac HC, (Bio-Rad Laboratories,
Calif, USA) for 2 hours. The membrane was incubated
withprimary polyclonalantibodyrabbitanti-GLP-1 receptor
α IgG (Santa Cruz Biotech., Calif, USA) (diluted 1/200)
for 1 hour. Three consecutive washes with Tris/Tween
solution, after which the membrane was incubated with the
secondary antibody, mouse antirabbit IgG-HRP 2◦ (Santa
Cruz Biotech.) (1/500)for 2 hours, thenwashed 4 times with
the same Tris/Tween solution. Equal volumes of reagents
A and B of chemiluminescence solution were mixed and
pouredontothemembrane.The immunoblottedbandswere
later developed on a Fuji Medical X-ray ﬁlm (Agfa-Gevaert
N.V., Mortsel, Belgium).
3.Results
3.1. Body Weights. The mean body weights for the seven rat
groups after one month of treatment are shown in Figure 3.
One can observe the signiﬁcant decrease (P<. 001) in the
body weight of all diabetic groups compared to the normal.4 Experimental Diabetes Research
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Figure 4: Mean ratios of heart weight per body weight of the seven
rat groups after 1 month. ∗indicates no signiﬁcance compared with
normalgroup (N = 16).
3.2. Cardiac Hypertrophy Was Assessed Macroscopically. The
mean ratios of heart weight to body weights are represented
in Figure 4. The data show a signiﬁcantly increased heart
weight to body weight ratio in all the diabetic groups
compared to the normal (D, DI, DE, DIA, DEA) except the
group treated with Aliskiren (DA).
3.3. Plasma Glucose and GLP-1 Levels. There was a signif-
icant increase in plasma glucose levels in all the diabetic
groups compared to the normal. It is notable that 12.5% of
the Aliskiren-treated group exhibited normal blood glucose
levels after one month of treatment. GLP-1 levels in the
plasma of normal rats were assessed by ELISA,and a range of
7–9pM was observed with no signiﬁcant variation through-
out a month. Upon the induction of diabetes mellitus,
however, GLP-1 levels increased with a maximum peak of
28pM at day 28, compared to that of the normal. GLP-
1 levels of diabetic rats treated with Insulin (DI), Exendin
(DE), or Aliskiren (DA) were normalized. The combination
of Aliskiren with Insulin (DIA) was shown to be better
than the combination of Exendin-4 and Aliskiren (DEA),
because it corrected and nearly normalized GLP-1 levels in
the diabetic rats (Figure 5).
3.4. Binding Kinetics of GLP-1 to Its Receptor on the
Coronary Endothelium and Cardiomyocytes after One Month
of Treatment. Time-dependent radioactive GLP-1 ([125I]-
GLP-1) concentration curves of all the animal models
were mathematically curve-ﬁtted using a ﬁrst-order Bessel
function physical model describing a 1:1 stoichiometry for
reversible binding of GLP-1 with its receptor [16]. These
curves were used to determine the GLP-1 forward binding
constant (kn), reversal constant (k−n), dissociation constant
(Kd = k−n/kn), and the aﬃnity time constant (τ = 1/k−n)
with its receptor on the coronary endothelium cells and
cardiomyocytes [16, 17]. The derived Kd and τ values at
the coronary endothelium are represented in Table 1,a n d
those values at the cardiomyocyte level are represented in
Table 2. One can notice the extremely signiﬁcant increase
in Kd constant in the diabetic untreated (D), treated with
GLP-1
Glucose
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Figure 5: Plasma glucose (N = 24) and glucagon-like peptide-
1l e v e l s( N= 6) in all the animal groups after one month of
treatment. ∗indicates signiﬁcance with P<. 05 compared with
Glucose level of diabetic (D); #indicates extreme signiﬁcance with
P<. 001 compared with GLP-1 level of normal (N).
Table 1: The calculated dissociation constants (Kd) and binding
aﬃnity constants (τ) of glucagon-like peptide-1 (GLP-1) with its
receptor at the coronary endothelium (N = 8).
Rat Group Kd (moles × 10−15) τ (min)
Normal (N) 0.069 ± 0.005a 1.14 ±0.065a 
Diabetic (D) 0.700 ± 0.029b 0.37 ±0.007
b 
Diabetic + Insulin (DI) 0.110 ± 0.025c 2.17 ±0.23c 
Diabetic + Exendin-4 (DE) 0.580 ± 0.029d 0.45 ± 0.01
d 
Diabetic +Aliskiren (DA) 0.857 ± 0.043e 0.38 ±0.007e 
Diabetic + Exendin-4
+A l i s k i r e n( D E A ) 0.230 ± 0.039f 1.35 ± 0.0913
f 
Diabetic + Insulin
+A l i s k i r e n( D I A ) 0.650 ± 0.068g 0.657 ±0.021
g 
Coronary endothelium: dissociation constants signiﬁcant at P<. 05 for (a,
f), (b, d), (b, e), (c, f) and P<. 001for (a,b), (a,d), (a, e),(a,g), (b, c), (b, f),
(c, d), (c, e), (c, g), (d, e), (d, f), (e, f), (f, g). The other comparative values
are not signiﬁcant (P>. 05). Binding aﬃnities signiﬁcant at P<. 05 for (c ,
f )a n dP<. 001 for (a ,b  ), (a ,c  ), (a ,d  ), (a ,e  ), (a ,g  ), (b ,c  ), (b ,
d ),(b ,f  ),(b ,g  ), (c ,d  ),(c ,e  ),(c ,g  ),(d ,e  ), (d ,f  ),(d ,g  ),(e ,f  ),
(e ,g  ), (f ,g  ). The other comparative values are not signiﬁcant (P>. 05).
Exendin-4 (DE), treated with Aliskiren (DA), cotreated with
Exendin-4 and Aliskiren (DEA), and cotreated with Insulin
and Aliskiren (DIA) compared to the normal. However,
diabetic treated with Insulin (DI) showed no signiﬁcance
compared to the normal. Diabetes decreased the τ value on
CE and increased it on CM compared to normal. Exendin-
4 treatment partially corrected τ value in both CE and CM.
Aliskiren treatment did not alter τ from diabetics in the CE,
but its combination with Exendin-4 normalized it.
3.5. Western Blot Analysis. Western blotting was assessed to
determine the expression variation of GLP-1 receptor in the
heart. The GLP-1 receptor band densities were measured
using ImageJ program. The housekeeping gene, β-actin, was
also blotted, and a mean ratio was done to correct any
diﬀerences in loading of the proteins. Our data showed noExperimental Diabetes Research 5
Table 2: The calculated dissociation constants (Kd) and binding
aﬃnity constants (τ) of glucagon-like peptide-1 (GLP-1) with its
receptor at the cardiomyocytes (N = 8).
Rat group Kd (moles × 10−15) τ (min)
Normal (N) 0.64 ± 0.021a 0.34 ± 0.005a 
Diabetic (D) 0.33 ± 0.018b 0.6 ± 0.018
b 
Diabetic + Insulin (DI) 0.47 ± 0.019c 0.43 ±0.009c 
Diabetic + Exendin-4 (DE) 0.59 ± 0.025d 0.41 ±0.0084
d 
Diabetic + Aliskiren (DA) 0.12 ± 0.014e 1.37 ±0.0938
e 
Diabetic + Exendin-4
+A l i s k i r e n( D E A ) 0.077 ± 0.01f 1.63 ±0.13
f 
Diabetic + Insulin
+A l i s k i r e n( D I A ) 0.19 ± 0.027g 1.33 ±0.08
g 
Cardiomyocytes: dissociation constants signiﬁcant at P<. 05 for (b, c), (b,
g ) ,( c ,d ) ,( e ,f ) ,( f ,g )a n dP<. 001 for (a, b), (a, c), (a, e), (a, f), (a, g),
(b, d), (b, e), (b, f), (c, e), (c, f), (c, g), (d, e), (d, f), (d, g), (f, g). The
other comparative values are not signiﬁcant (P>. 05). Binding aﬃnities
signiﬁcant at P<. 001 for (a ,b  ), (a ,c  ), (a ,d  ), (a ,e  ), (a ,f  ), (a ,g  ),
(b ,c  ), (b ,d  ), (b ,e  ), (b ,f  ), (b ,g  ), (c ,e  ), (c ,f  ), (c ,g  ), (d ,e  ),
(d ,f  ), (d ,g  ). The other comparative values are not signiﬁcant (P>. 05).
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Figure 6: A representative Western blot GLP-1 receptor bands, β-
actin bands and their mean ratio (N = 6).
signiﬁcant change in the densities of GLP-1 receptor bands
between the normal and the treated groups (Figure 6).
4.Discussion
The GLP-1 receptor has been localized in many tissues,
including the heart [4] .R e c e n t l y ,i tw a ss h o w nt h a tt h i s
(GLP-1) receptor is absent in the mouse cardiac ﬁbroblasts,
but, abundant in the endocardium. Moreover, endothelium
and coronary smooth muscle cells of the heart were also
s h o w nt ob e a rG L P - 1r e c e p t o r s[ 18]. Upon binding to its
receptor, GLP-1 produces numerous eﬀects, but because of
its very short physiologic half-life, its use as a therapeutic
agent is not practical [19]. Incretin mimetics have been
introduced in the market to be used as therapies for diabetes
mellitus [20]. Our study aimed at assessing the modulation
of GLP-1 receptor upon the usage of diﬀerent treatment
modalities including insulin, Exendin-4 (GLP-1 receptor
agonist), and Aliskiren (potent renin inhibitor).
After one month of treatment, body weights of the rats
in each group were recorded and our results showed a signif-
icant decrease in body weights of all diabetic rats compared
tothenormal. Thiscanbeexplained bytheprocessofmuscle
wasting that occurs in diabetic patients [21]. Interestingly,
diabetic rats treated with Exendin-4 showed a signiﬁcant
increase in their body weight compared to the diabetic
untreated (Figure 3). Moreover, Cardiac hypertrophy was
assessed macroscopically (Figure 4); the ratio of heart weight
to body weight revealed that there is a signiﬁcant increase
in most diabetic rats compared to that of the normal. This
indicated the presence of cardiac hypertrophy in the diabetic
rats.However,heartweightoverbodyweightratioofdiabetic
rats treated with Aliskiren showed no signiﬁcance when
compared to the ratio of normal. One can conclude that the
beneﬁcial eﬀect of Aliskiren as a cardioprotective agent is
manifested [13].
Blood glucose levels were extremely increased in all
diabetic groups treated or untreated (Figure 5). The intra-
venous injection of streptozotocin (STZ)—a glucosamine-
nitrosourea antibiotic with structural similarity to glucose
that is readily taken up by the pancreatic β cells—causes β
cells toxicity and ultimately necrosis, leading to deﬁciency in
insulin secretion. The use of Streptozotocin to induce type
1d i a b e t e si nr a t si sa d v a n t a g e o u s ,b e c a u s ei ti se a s y ,f a s t ,
and the eﬀect of diabetes on the heart can be evaluated [22].
Our aim was to assess the long-term eﬀects of treatments on
blood glucose level in type 1 diabetic rats. It is not surprising
that after one month of insulin treatment blood glucose
levels of the diabetic rats were not lowered/corrected, since
insulin directly treats diabetes on a daily basis—as a short-
term and not a long-term treatment. Insulin glargine may be
expected to lower the blood glucose levels since it is a long-
acting insulin; however, the duration of its action does not
reach 24 hours with some recipients, which may be reﬂected
by hyperglycemia [23]. Although not signiﬁcant, Exendin-4
treatment showed slight improvement in the blood glucose
levels. On the other hand, Aliskiren treatment signiﬁcantly
decreased blood glucose levels compared to the untreated.
In fact, administration of Aliskiren alone normalized blood
glucose levels of 12.5% of the treated rats. Recent studies
have shown that Aliskiren improves insulin sensitivity in
type 2 diabetic mice [24]; however, there are no reports on
Aliskiren’seﬀectonbloodglucoseintype1diabetesmellitus.
The diﬀerent combinations of Aliskiren with insulin or
Exendin-4, however, exhibited no beneﬁcial eﬀects on the
blood glucose levels compared to the normal.
GLP-1 levels in the plasma of normal rats showed a
range of 7–9pM with no signiﬁcant variation throughout a
month. Upon the induction of diabetes mellitus, however,
GLP-1 levels increased with a maximum peak of 28pM
at day 28, compared to that of the normal. GLP-1 levels
in diabetic rats treated with Insulin (DI), Exendin-4 (DE),
or Aliskiren (DA) were normalized. The combination of
Aliskiren with Insulin (DIA)was shown to be better than the
combination of Exendin-4 and Aliskiren (DEA), because it
corrected and nearly normalized GLP-1 levels in the diabetic
rats. It is possible that the DPP-IV enzyme is upregulated
in the diabetic state, thereby, inactivating GLP-1 molecules6 Experimental Diabetes Research
and reducing their aﬃnity to the receptors. Hence, GLP-1
secretion is enhanced in the diabetic state to overcome this
inactivation. Studies have reported that circulating DPPIV
enzyme activity and mRNA are both enhanced in STZ-
treated rats [25].
Rat heart perfusion technique showed an extremely
signiﬁcant decrease of GLP-1 aﬃnity to its receptor in the
diabetic state (D) compared to the normal (N) (1.14 ±
0.065min versus 0.37 ± 0.007min) at the level of the
coronary endothelium. In diabetic rats treated with insulin
(DI), GLP-1 aﬃnity to its receptor increased beyond the
normal (1.14 ± 0.065min versus 2.17 ± 0.23min), sug-
gesting a direct eﬀect of insulin on the GLP-1 receptor.
Treatment with Exendin-4 (DE) (0.45 ± 0.01min) slightly
enhanced, while Aliskiren (DA) (0.38 ± 0.007) showed no
signiﬁcant change in its aﬃnity compared to the diabetic(D)
(0.37 ± 0.007min). Interestingly, however, their combined
therapy (DEA) (1.35 ± 0.0913 min) normalized the aﬃnity
constant. The cotreatment with Insulin and Aliskiren (DIA)
showed some enhancement (0.657 ± 0.021min) but could
not be compared to the eﬀect executed by (DEA) (1.35 ±
0.0913min) (Table 1).
In parallel, it is interesting to note that the densities
of GLP-1 receptors in the heart obtained by the Western
blotting showed no diﬀerence between the normal or any of
the diabetic-treated groups (Figure 6), while heart perfusion
results showed diﬀerences in GLP-1 binding aﬃnity between
CMandCEinboththenormalandthediabeticrats(Tables1
and 2). At the level of the cardiomyocyte, our results showed
a signiﬁcant increase in the aﬃnity of GLP-1 to its receptor
in the diabetic compared to the normal and compared
to the CHAPS-untreated diabetic. It is possible that GLP-
1 receptors located on endothelial cells are diﬀerent from
thosepresentonthecardiomyocytes,suggestingtheexistence
of multiple subtypes of GLP-1 receptor, thereby explaining
the diﬀerence in aﬃnity constants in CHAPS-treated and -
untreated diabetic rats. Another possible explanation could
be that GLP-1 receptor expression is higher in the coronary
endothelium than in cardiomyocytes. Insulin and Exendin-4
treatments showed slight improvement in the aﬃnity (0.43
± 0.009min and 0.41 ± 0.0084min, resp.), butAliskiren and
its combination treatments (DEA) and (DIA) did not lower
the aﬃnity (Table 2).
These two ﬁndings could hint the possibility of diﬀerent
GLP-1 receptors existing in the coronary endothelium and
cardiomyocytes. In fact, there have been discussions about
the existence of a putative second GLP-1 receptor during a
European GLP-1 Club Meeting in Marseille, where scientists
haveconcludedthat“althoughnomolecularevidencehasyet
been presented, there are circumstantial data to suggest that
such receptors do exist” [26].
A c c o r d i n gt oN y s t r o me ta l .[ 27], GLP-1 receptors are
located on the human coronary endothelial cells. Binding of
GLP-1 to those receptors was reported to induce vasodila-
tion, probably mediated through Nitric Oxide production.
Furthermore, this eﬀect was eliminated upon the removal of
the endothelial lining [26]. Our results showed a signiﬁcant
reduction of GLP-1 aﬃnity to its receptor in the diabetic rat
coronary endothelium compared to the normal. It is also
probable that in the diabetic state, GLP-1 receptors on the
coronary endothelial cellsare modiﬁed in such a way thatthe
bindingaﬃnity ofGLP-1 tothemisreduced,hence,resulting
in reducedNO productionand subsequentvasoconstriction.
Moreover, this reduction in aﬃnity was corrected beyond
the normal by the treatment with insulin, suggesting a direct
role of insulin on GLP-1 receptor modulation. The aﬃnity
constant in the diabetic rats was improved with Exendin-4
treatment, however Aliskiren did not ameliorate it. Interest-
ingly, the combination of the two treatment modalities nor-
malized the aﬃnity suggesting synergy betweenthe Exendin-
4 and Aliskiren treatments. Recently, Dong et al. reported
that, upon the administration of Aliskiren, the potent renin
inhibitor, nitric oxide synthase production by endothelial
cells was signiﬁcantly restored [28]. In addition, GLP-1 in-
fusion has been reported to induce vasodilation [26]. Com-
bining Aliskiren and Exendin-4 probably causes an interac-
tion, resulting inanexaggerated eﬀecton thebinding aﬃnity
of GLP-1 to its receptor on the coronary endothelium.
5.Conclusions
Although many questions remain unanswered regarding the
GLP-1 analogue, Exendin-4 and the renin-inhibitor, Ali-
skiren, it is evident that treatment with both Exendin-4,
and Aliskiren greatly improves the GLP-1 binding aﬃnity at
the coronary endothelium level of the type 1 diabetic rat.
It is therefore crucial to further investigate and to try and
ﬁnd a common ground between GLP-1 signaling pathway
and the renin that could indicate a crosstalk between the
two. Moreover, future investigations are crucial to unmask
the possible existence of another GLP-1 receptor, hence ex-
plaining the diﬀerence in their aﬃnities at the CE and CM
levels. In conclusion, clinical studies on Aliskiren and/or
its combination with Exendin-4 in type 1 diabetes mellitus
could verify their long-term beneﬁciary eﬀects on blood
glucose levels and cardiomyopathy and further shed light on
their ability to prevent the progression of diabetic complica-
tions especially in the heart.
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